Tumor News and Research

RSS

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry assay by the Chinese Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI (crizotinib).

12 Sep 2013

Astrazeneca Licenses Merck's Cancer Candidate MK-1775

...

11 Sep 2013

Umbilical cord mesenchymal stem cells may have targeting capacity for glioma

Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide.

11 Sep 2013

Personalized treatment may be effective in wild type cancers

As a woman in her mid-forties who didn't smoke, Elizabeth Lacasia never expected to be diagnosed with lung cancer. But in 2006, after she developed a persistent and serious cough, a chest X-ray and CT scan revealed several tumors in her lower left lung.

11 Sep 2013

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Scientists from A*STAR's Singapore Immunology Network have discovered a new defense mechanism that the immune system utilises to combat infections. The team's discovery of how a novel protein unexpectedly activates an immune response shows how this mechanism can also be used to get rid of tumour cells.

11 Sep 2013

Researchers discover inherited gene mutation linked to childhood leukemia

Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.

11 Sep 2013

GGO-dominant lung tumors have excellent prognosis

Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe.

10 Sep 2013

Chemists Find New Way To Put The Brakes On Cancer

...

10 Sep 2013

Metamark reports positive results from clinical validation study of prostate cancer prognostic test

Metamark Genetics, Inc., a privately-held biotechnology company, today announced positive results from a large clinical validation study of ProMark, its biopsy-based prostate cancer prognostic test.

10 Sep 2013

Novel viral therapy to treat specific types of cancer in children

Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children's Hospital, however, are looking into how those same types of common viruses can actually help treat a child who is diagnosed with certain cancers.

10 Sep 2013

Biologists identify two pathways via which chromosomes are rearranged

Biologists reported today in Nature that they have identified two pathways through which chromosomes are rearranged in mammalian cells. These types of changes are associated with some cancers and inherited disorders in people.

10 Sep 2013

Little STING could go long way in avoiding arthritis, type 1 diabetes, report researchers

A little STING could go a long way in helping treat or even avoid autoimmune diseases such as arthritis, type 1 diabetes and multiple sclerosis, researchers report.

10 Sep 2013

New drug delivery system using NDs allows for direct application of chemotherapy to brain tumors

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new drug delivery system using nanodiamonds (NDs) that allows for direct application of chemotherapy to brain tumors with fewer harmful side effects and better cancer-killing efficiency than existing treatments.

10 Sep 2013

Ferritin protects kidneys against damage by controlling iron

A protein, ferritin, protects kidneys against a damaging after-effect of injury, heart failure or hardened arteries by controlling levels of iron, according to a study published today by researchers at the University of Alabama at Birmingham in the Journal of Clinical Investigation.

10 Sep 2013

Researchers investigate importance of STAT1 phosphorylation in NK cells

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens.

7 Sep 2013

Software manipulates 3-D holograms of various organs obtained from ultrasound, CT or MRI scans

Recently converted in one of the youngest residents of Silicon Valley, California, the high-tech Mexican enterprise Echopixel created software that allows the medical doctor to look and manipulate on their desk third dimension (3-D) holograms of various organs obtained from ultrasound, CT or MRI scans.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Researchers start Phase I clinical trial of implantable vaccine for treatment of melanoma

A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

BMP linked to increased risk of benign tumors, not cancers

Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Sep 2013